Quick Takeaways:
- Parnell Technologies has launched nixiFLOR in the US following approval from the US FDA for the treatment of bovine respiratory disease (BRD) and control of BRD-associated fever in beef and non-lactating dairy cattle
- nixiFLOR is the first FDA-approved generic of Resflor Gold, demonstrating bioequivalence with the same active ingredients (florfenicol and flunixin meglumine), offering a cost-effective alternative for veterinarians and producers
- The dual-action injectable combines antimicrobial and anti-inflammatory effects in a single dose, improving treatment efficiency, reducing labor, and supporting faster recovery and productivity in cattle operations
Why It Matters?
nixiFLOR gives vets and producers a lower‑cost, first‑generic alternative to Resflor Gold with the same florfenicol–flunixin combo and FDA‑confirmed bioequivalence for BRD treatment and BRD‑associated fever in beef and non‑lactating dairy cattle.
By combining antimicrobial and anti‑inflammatory action in a single subcutaneous dose (with a defined 38‑day withdrawal period), the product simplifies BRD protocols, reduces handling and labor, and supports quicker clinical recovery while maintaining food-safety assurances for edible tissues.
Source: Businesswire
